A Superdevice for Mental Health
OAK, the apex brain stimulation wearable for neuropsychiatric and cognitive health, is the result of 15 years of clinical research and product development, millions of hours of real-world testing, and a groundbreaking collaboration with the design and engineering teams behind Beats and Nest.
Clinically Proven
Completed clinical research includes an 8-week real-world anxiety study involving 164 active-duty first responders (pending publication), a triple-blind, randomized, sham-controlled trial for Major Depressive Disorder published in The Journal of Clinical Psychiatry (2024), and multiple pilot studies investigating treatment of chronic insomnia, Bipolar II Depression, Parkinson’s Disease, and Substance Use Disorder.
Proof-of-Concept
Over 60,000 patients have used OAK’s predecessor—a proof-of-concept device prescribed under temporary FDA clearance by more than 14,000 providers and reimbursed by Medicaid (MaineCare). No other wearable brain stimulation technology has undergone comparable real-world testing—experience that directly informed every aspect of OAK’s perfected design.
Leadership
Kelly Roman
CO-FOUNDER, CEO, DIRECTOR
The son of a US Army veteran, Kelly graduated from Harvard College and has helped pioneer the wearable brain stimulation category since 2009, with a passion for clinical research, product development, regulatory affairs, manufacturing, and patient advocacy.
Kelly led OAK product development in collaboration with the teams behind Beats, Nest and the Microsoft HoloLens. Kelly also spearheaded the company's partnerships with the Seattle Police Department and Dr. Maurizio Fava, Psychiatrist-in-Chief of Massachusetts General Hospital, to design and conduct pivotal trials in support of regulatory approval.
Chip Fisher
FOUNDER, CHAIRMAN, DIRECTOR
Angel Investor, Philanthropist, Juilliard Artist Program Board Member, Harvard College Class of 1978.
Advisors
Maurizio Fava, MD
ADVISOR
Psychiatrist-In-Chief, Department of Psychiatry, Massachusetts General Hospital (MGH) | Director, Division of Clinical Research, Mass General Research Institute | Executive Director, Clinical Trials Network & Institute | Associate Dean for Clinical & Translational Research, Slater Family Professor of Psychiatry, Harvard Medical School
David Shulkin, MD
ADVISOR
Former US Secretary of Veterans Affairs | Former CEO of Beth Israel Medical Center.
Joan Camprodon-Gimenez, MD, PhD, MPH
ADVISOR
Chief, Division of Neuropsychiatry, MGH | Director, Transcranial Magnetic Stimulation (TMS) Clinical Service, MGH | Director, Laboratory for Neuropsychiatry & Neuromodulation, MGH | Associate Professor of Neurology, Harvard Medical School | Associate Professor of Psychiatry, Harvard Medical School